Sun Pharma API Division
✓ 已认证供应商Mumbai, India · 出口市场: US,EU,WHO
认证于 2026年8月9日
产品
3
生产基地
2
Sun Pharma API Division operates GMP-certified manufacturing facilities producing APIs and intermediates for regulated markets.
Regulatory history
No regulatory action on record
Sourced from openFDA and the EudraGMDP register — not self-declared by the supplier.
Nothing on record for this organisation.
Performance on PharmaLink
4 of 9 metrics have enough data
On-time delivery
Not enough data
No completed orders yet
Response rate
133%
8 of 6 inquiries
Answered within 24h
63%
5 of 8 answered inquiries
Quote win rate
25%
2 of 8 quotes submitted
Dispute rate
Not enough data
No completed orders yet
Repeat buyer rate
Not enough data
Only 1 buyers — too few to rate
Completed orders
0
On PharmaLink
Average order value
Not enough data
No completed orders yet
Time on PharmaLink
2m
Joined 2026-08-09
These measure activity on PharmaLink only, not the supplier’s whole business. Rates are withheld below five samples — one delivery on time is one delivery, not a 100% record.
Commercial terms
- Incoterms offered
- CIF · DAP · DDP · FOB · FOB MumbaiUsed on closed deals: FOB Mumbai
- Payment terms
- 30% advance, 70% against BL
- Standard lead time
- 2–3 weeks
- Lowest minimum order
- 25 kgAcross live listings; per-product MOQ may be higher.
- Samples
- Available on 1 listing(s)
- Cold chain
- ambient
Terms are supplier-stated defaults. The binding terms are the ones on a quote you accept.
认证证书
| 认证证书 | Status | Expiry | Source |
|---|---|---|---|
| US FDA GMP | ✓ | 2028年4月 | FDA drug database |
| EU GMP | ✓ | 2026年9月 | EudraGMDP |
| WHO PQ | ✓ | 2029年2月 | WHO PQ list |
| Manufacturing licence (Form 25/28) | ✓ | 2029年8月 | State FDA register |
生产基地
| 厂址 | FDA FEI 编号 | GMP 状态 | 最近一次检查 | 产能 |
|---|---|---|---|---|
| Mumbai Unit-1Mumbai, India · manufacturing | 3002807546 | FDA Current (Active)EU Current (Active) | NAI (No Action Indicated)2025年9月 | 2400 MT/year· 65% |
| Ankleshwar API Facility (Unit II)Ankleshwar, India · manufacturing | 3002808041 | FDA Current (Active) | VAI (Voluntary Action Indicated)2026年3月 | 900 MT/year· 48% |
注册申报
贵司注册团队可在申报中引用的文件。请在签发机构的官方数据库中逐一核实编号。
| 类型 | 编号 | 产品 | Status | 有效期 |
|---|---|---|---|---|
| CEP (EDQM) | CEP 2019-021-3-0可供引用 | Paracetamol (Acetaminophen) | active | 2026年8月剩余 -34 天 |
| US FDA ANDA | ANDA 200123 | Ibuprofen | expired | 2026年5月剩余 -144 天 |
| US FDA Type II DMF | Type II DMF #23412可供引用· 已被 48 项引用 | Paracetamol (Acetaminophen) | active | 无有效期 |
关键联系人
请以已认证买家身份登录以查看商务邮箱。
Mr. Suresh Kumar
Vice President - International API Exports · Global API Business
Dr. Meera Iyer
Head of Regulatory Affairs · Regulatory
产品
- 💊
Paracetamol (Acetaminophen)
CAS 103-90-2 · IP / BP / USP · 起订量 25 kg
$4.2–5.1/kg
- 💊
Ibuprofen
CAS 15687-27-1 · BP / USP · 起订量 25 kg
$6.1–7.4/kg
- 💊
Dicyandiamide (DCDA)
CAS 461-58-5 · Technical · 起订量 1000 kg
$2.8–3.2/kg
评价4.5(2)
- ★★★★★MediSource Global· Singapore
Strong quality, pricing negotiable
Good regulatory coverage; price came down after a short negotiation.
Regulatory complianceCommunication - ★★★★★Cipla Ltd· India✓ 已认证买家
Consistently reliable on Metformin
CoAs always in order and lead times as promised. Documentation is top-notch.
QualityDocumentationOn-time delivery